Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) COO Sells 12,500 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 12,500 shares of the firm’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $19.66, for a total value of $245,750.00. Following the sale, the chief operating officer directly owned 200,641 shares of the company’s stock, valued at $3,944,602.06. This trade represents a 5.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Ryan Cohlhepp also recently made the following trade(s):

• On Tuesday, March 3rd, Ryan Cohlhepp sold 17,392 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.16, for a total value of $315,838.72.
• On Thursday, January 22nd, Ryan Cohlhepp sold 3,828 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.10, for a total value of $69,286.80.
• On Thursday, January 15th, Ryan Cohlhepp sold 149 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.02, for a total value of $2,684.98.

Bicara Therapeutics Price Performance

NASDAQ:BCAX traded down $0.08 during mid-day trading on Tuesday, reaching $19.32. The stock had a trading volume of 243,139 shares, compared to its average volume of 504,146. The stock has a market cap of $1.06 billion, a P/E ratio of -8.62 and a beta of -0.78. The business’s 50 day moving average is $16.84 and its 200 day moving average is $16.14. Bicara Therapeutics Inc. has a fifty-two week low of $7.80 and a fifty-two week high of $20.25.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Citizens Jmp assumed coverage on shares of Bicara Therapeutics in a research note on Thursday, January 29th. They set a “market perform” rating and a $31.00 price target on the stock. Mizuho raised shares of Bicara Therapeutics to a “hold” rating in a research note on Thursday, December 18th. BTIG Research reiterated a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Friday, January 9th. Finally, UBS Group reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Bicara Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $30.25.

Hedge Funds Weigh In On Bicara Therapeutics

A number of institutional investors have recently made changes to their positions in BCAX. Caitong International Asset Management Co. Ltd lifted its position in shares of Bicara Therapeutics by 385.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock worth $97,000 after purchasing an additional 4,585 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its stake in shares of Bicara Therapeutics by 596.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock worth $54,472,000 after acquiring an additional 2,771,868 shares during the last quarter. Invesco Ltd. increased its position in Bicara Therapeutics by 20.6% during the fourth quarter. Invesco Ltd. now owns 21,006 shares of the company’s stock worth $354,000 after acquiring an additional 3,595 shares during the period. VARCOV Co. bought a new stake in Bicara Therapeutics in the 4th quarter valued at $263,000. Finally, Virtus Investment Advisers LLC grew its position in Bicara Therapeutics by 46.4% in the 4th quarter. Virtus Investment Advisers LLC now owns 14,395 shares of the company’s stock worth $242,000 after purchasing an additional 4,560 shares during the last quarter.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.